Phase I dose finding studies of an adjuvanted Clostridium difficile toxoid vaccine

Richard N. Greenberg, Thomas C. Marbury, Ginamarie Foglia, Michel Warny

Research output: Contribution to journalArticlepeer-review

79 Scopus citations


Fifty healthy adult (18-55 years) and 48 elderly (≥65 years) volunteers were randomized to receive a candidate Clostridium difficile toxoid vaccine (2 μg, 10 μg, or 50 μg) or placebo on Days 0, 28, and 56. No volunteer receiving placebo seroconverted. For toxin A, seroconversion by Day 56 (post-dose 2) was observed in 100% of volunteers aged 18-55 years in all dose groups and in 50%, 89%, and 100% of elderly participants in the 2 μg, 10 μg, and 50 μg dose groups, respectively. For both age groups, seroconversion for toxin B was lower than toxin A. There were no safety concerns.

Original languageEnglish
Pages (from-to)2245-2249
Number of pages5
Issue number13
StatePublished - Mar 16 2012

Bibliographical note

Copyright 2012 Elsevier B.V., All rights reserved.


  • Clostridium difficile
  • Dose finding
  • Immunogenicity
  • Safety
  • Vaccine

ASJC Scopus subject areas

  • Molecular Medicine
  • General Immunology and Microbiology
  • General Veterinary
  • Public Health, Environmental and Occupational Health
  • Infectious Diseases


Dive into the research topics of 'Phase I dose finding studies of an adjuvanted Clostridium difficile toxoid vaccine'. Together they form a unique fingerprint.

Cite this